Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Oncogene ; 36(43): 6030-6040, 2017 10 26.
Artigo em Inglês | MEDLINE | ID: mdl-28671672

RESUMO

Cancer cells reprogram their metabolism to maintain both viability and uncontrolled proliferation. Although an interplay between the genetic, epigenetic and metabolic rewiring in cancer is beginning to emerge, it remains unclear how this metabolic plasticity occurs. Here, we report that in prostate cancer cells (PCCs) microRNAs (miRNAs) greatly contribute to deregulation of mitochondrial fatty acid (FA) oxidation via carnitine system modulation. We provide evidence that the downregulation of hsa-miR-124-3p, hsa-miR-129-5p and hsa-miR-378 induced an increase in both expression and activity of CPT1A, CACT and CrAT in malignant prostate cells. Moreover, the analysis of human prostate cancer and prostate control specimens confirmed the aberrant expression of miR-124-3p, miR-129-5p and miR-378 in primary tumors. Forced expression of the miRNAs mentioned above affected tumorigenic properties, such as proliferation, migration and invasion, in PC3 and LNCaP cells regardless of their hormone sensitivity. CPT1A, CACT and CrAT overexpression allow PCCs to be more prone on FA utilization than normal prostate cells, also in the presence of high pyruvate concentration. Finally, the simultaneous increase of CPT1A, CACT and CrAT is fundamental for PCCs to sustain FA oxidation in the presence of heavy lipid load on prostate cancer mitochondria. Indeed, the downregulation of only one of these proteins reduces PCCs metabolic flexibility with the accumulation of FA-intermediate metabolites in the mitochondria. Together, our data implicate carnitine cycle as a primary regulator of adaptive metabolic reprogramming in PCCs and suggest new potential druggable pathways for prevention and treatment of prostate cancer.


Assuntos
Carnitina O-Palmitoiltransferase/genética , Proteínas de Membrana Transportadoras/genética , MicroRNAs/genética , Neoplasias da Próstata/genética , Carcinogênese/genética , Carnitina/metabolismo , Linhagem Celular Tumoral , Proliferação de Células/genética , Ácidos Graxos/genética , Ácidos Graxos/metabolismo , Regulação Neoplásica da Expressão Gênica , Humanos , Masculino , Oxirredução , Neoplasias da Próstata/metabolismo , Neoplasias da Próstata/patologia
2.
Spectrochim Acta A Mol Biomol Spectrosc ; 173: 476-488, 2017 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-27718451

RESUMO

Hyperspectral Raman images of human prostatic cells have been collected and analysed with several approaches to reveal differences among normal and tumor cell lines. The objective of the study was to test the potential of different chemometric methods in providing diagnostic responses. We focused our analysis on the ν(CH) region (2800-3100cm-1) owing to its optimal Signal-to-Noise ratio and because the main differences between the spectra of the two cell lines were observed in this frequency range. Multivariate analysis identified two principal components, which were positively recognized as due to the protein and the lipid fractions, respectively. The tumor cells exhibited a modified distribution of the cytoplasmatic lipid fraction (mainly localized alongside the cell boundary) which may result very useful for a preliminary screening. Principal Component analysis was found to provide high contrast and to be well suited for image-processing purposes. Self-Modelling Curve Resolution made available meaningful spectra and relative-concentration values; it revealed a 97% increase of the lipid fraction in the tumor cell with respect to the control. Finally, a univariate approach confirmed significant and reproducible differences between normal and tumor cells.


Assuntos
Próstata/citologia , Neoplasias da Próstata/patologia , Análise de Célula Única/métodos , Análise Espectral Raman/métodos , Linhagem Celular , Linhagem Celular Tumoral , Humanos , Processamento de Imagem Assistida por Computador/métodos , Análise dos Mínimos Quadrados , Masculino , Análise Multivariada , Análise de Componente Principal , Próstata/química , Processamento de Sinais Assistido por Computador , Razão Sinal-Ruído
3.
J Dent Res ; 94(8): 1099-105, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25924857

RESUMO

Fluoride-releasing restorative dental materials can be beneficial to remineralize dentin and help prevent secondary caries. However, the effects of fluoride release from dental materials on the activity of dental pulp stem cells are not known. Here we investigate whether different fluoride release kinetics from dental resins supplemented with modified hydrotalcite (RK-F10) or fluoride-glass filler (RK-FG10) could influence the behavior of a human dental pulp stem cell subpopulation (STRO-1(+) cells) known for its ability to differentiate toward an odontoblast-like phenotype. The 2 resins, characterized by similar physicochemical properties and fluoride content, exhibited different long-term fluoride release kinetics. Our data demonstrate that long-term exposure of STRO-1(+) cells to a continuous release of a low amount of fluoride by RK-F10 increases their migratory response to transforming growth factor ß1 (TGF-ß1) and stromal cell-derived factor 1 (SDF-1), both important promoters of pulp stem cell recruitment. Moreover, the expression patterns of dentin sialoprotein (dspp), dentin matrix protein 1 (dmp1), osteocalcin (ocn), and matrix extracellular phosphoglycoprotein (mepe) indicate a complete odontoblast-like cell differentiation only when STRO-1(+) cells were cultured on RK-F10. On the contrary, RK-FG10, characterized by an initial fluoride release burst and reduced lifetime of the delivery, did not elicit any significant effect on both STRO-1(+) cell migration and differentiation. Taken together, our results highlight the importance of taking into account fluoride release kinetics in addition to fluoride concentration when designing new fluoride-restorative materials.


Assuntos
Cariostáticos/farmacocinética , Materiais Dentários/química , Polpa Dentária/citologia , Fluoretos/farmacocinética , Odontogênese/efeitos dos fármacos , Células-Tronco/efeitos dos fármacos , Hidróxido de Alumínio/química , Diferenciação Celular/efeitos dos fármacos , Movimento Celular/efeitos dos fármacos , Células Cultivadas , Quimiocina CXCL12/farmacologia , Proteínas da Matriz Extracelular/metabolismo , Glicoproteínas/metabolismo , Humanos , Cinética , Hidróxido de Magnésio/química , Osteocalcina/metabolismo , Fenótipo , Fosfoproteínas/metabolismo , Reação em Cadeia da Polimerase em Tempo Real , Saliva Artificial/química , Sialoglicoproteínas/metabolismo , Células-Tronco/citologia , Fator de Crescimento Transformador beta1/farmacologia
4.
Stem Cell Res ; 10(1): 85-94, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23142801

RESUMO

Neural stem cells (NSCs) raised the hope for cell-based therapies in human neurodevelopmental and neurodegenerative diseases. Current research strategies aim to isolate, enrich, and propagate homogeneous populations of neural stem cells. Unfortunately, several concerns with NSC cultures currently may limit their therapeutic promise. Exhaustion of growth factors and/or their uncontrolled release with burst and fall in their concentration may greatly affect the in vitro behavior of NSCs. In this context, we investigate whether a device containing heparan sulfate (HS), which is a co-factor in growth factor-mediated cell proliferation and differentiation, could potentiate and prolong the delivery of fibroblast growth factor-2 (FGF-2) and thus improve in vitro NSC cultivation. We demonstrated that NSCs cultivated in media with a controlled release of FGF-2 from a polyelectrolyte polymer showed a higher proliferation rate, and reduced apoptosis and senescence. In these experimental conditions NSCs preserve their stemness properties for a longer period of time compared with controls. Also of interest is that cell fate properties are conserved as well. The controlled release of FGF-2 reduced the level of oxidative stress and this is associated with a lower level of damaged DNA. This result may explain the reduced level of senescence and apoptosis in NSCs cultivated in the presence of hydrogel-releasing FGF-2.


Assuntos
Técnicas de Cultura de Células/métodos , Fator 2 de Crescimento de Fibroblastos/farmacologia , Células-Tronco Neurais/efeitos dos fármacos , Animais , Diferenciação Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Eletrólitos/química , Heparitina Sulfato/química , Hidrogel de Polietilenoglicol-Dimetacrilato/química , Cinética , Camundongos , Células-Tronco Neurais/citologia , Polímeros/química
5.
Urologia ; 77(2): 71-83, 2010.
Artigo em Italiano | MEDLINE | ID: mdl-20890863

RESUMO

Androgens are involved in the development and progression of prostate cancer even if the mechanism is not well-recognized. For this reason androgen-deprivation therapy remains a milestone for the treatment of patients with advanced and metastatic disease and, in the last years, in conjunction with radiotherapy and surgery in locally advanced tumors. Alternative options, such as intermittent deprivation suppression, seem to be promising in terms of clinical benefits and toxicity profile. However, current therapies present side effects, such as testosterone surge with consequent clinical flare-up, metabolic syndrome and hormone-resistance, which develops after a variable number of years. Novel therapies such as LH-RH antagonists and prolonged depot LH-RH analogues have been developed in order to avoid clinical flare-up and testosterone microsurges. Novel androgen synthesis inhibitors, such as abiraterone acetate and MDV3100, have been recently discovered and tested as promising hormonal second-line agents in patients with castration-resistant prostate cancer. Finally, long-term side effects from androgen deprivation, such as osteoporosis, sarcopenic obesity and cardiovascular morbidity should be carefully monitored and properly treated.


Assuntos
Inibidores de 5-alfa Redutase/uso terapêutico , Adenocarcinoma/tratamento farmacológico , Antagonistas de Androgênios/uso terapêutico , Androgênios , Antineoplásicos Hormonais/uso terapêutico , Hormônio Liberador de Gonadotropina/agonistas , Hormônio Liberador de Gonadotropina/antagonistas & inibidores , Neoplasias Hormônio-Dependentes/tratamento farmacológico , Neoplasias da Próstata/tratamento farmacológico , Inibidores de 5-alfa Redutase/efeitos adversos , Adenocarcinoma/fisiopatologia , Adenocarcinoma/terapia , Antagonistas de Androgênios/efeitos adversos , Androgênios/fisiologia , Androstenos , Androstenóis/uso terapêutico , Antineoplásicos Hormonais/efeitos adversos , Benzamidas , Quimioterapia Adjuvante , Terapia Combinada , Esquema de Medicação , Resistencia a Medicamentos Antineoplásicos , Feminização/induzido quimicamente , Hormônio Liberador de Gonadotropina/análogos & derivados , Humanos , Masculino , Terapia Neoadjuvante , Proteínas de Neoplasias/efeitos dos fármacos , Proteínas de Neoplasias/fisiologia , Neoplasias Hormônio-Dependentes/terapia , Nitrilas , Orquiectomia , Feniltioidantoína/análogos & derivados , Feniltioidantoína/uso terapêutico , Neoplasias da Próstata/fisiopatologia , Neoplasias da Próstata/terapia , Receptores Androgênicos/efeitos dos fármacos , Receptores Androgênicos/fisiologia , Testosterona/antagonistas & inibidores , Testosterona/biossíntese , Testosterona/metabolismo
6.
Urologia ; 77(2): 92-9, 2010.
Artigo em Italiano | MEDLINE | ID: mdl-20890867

RESUMO

Several substances such as growth hormone (GH), erythropoietin (Epo), and anabolic steroids (AS) are improperly utilized to increase the performance of athletes. Evaluating the potential cancer risk associated with doping agents is difficult since these drugs are often used at very high doses and in combination with other licit or illicit drugs. The GH, via its mediator, the insulin-like growth factor 1 (IGF-1), is involved in the development and progression of cancer. Animal studies suggested that high levels of GH/IGF-1 increase progression of androgen-independent prostate cancer. Clinical data regarding prostate cancer are mostly based on epidemiological studies or indirect data such as IGF-1 high levels in patients with prostate cancer. Even if experimental studies showed a correlation between Epo and cancer, no clinical data are currently available on cancer development related to Epo as a doping agent. Androgens are involved in prostate carcinogenesis modulating genes that regulate cell proliferation, apoptosis and angiogenesis. Most information on AS is anecdotal (case reports on prostate, kidney and testicular cancers). Prospective epidemiologic studies failed to support the hypothesis that circulating androgens are positively associated with prostate cancer risk. Currently, clinical and epidemiological studies supporting association between doping and urological neoplasias are not available. Nowadays, exposure to doping agents starts more prematurely with a consequent longer exposition period; drugs are often used at very high doses and in combination with other licit or illicit drugs. Due to all these elements it is impossible to predict all the side effects, including cancer; more detailed studies are therefore necessary.


Assuntos
Anabolizantes/efeitos adversos , Dopagem Esportivo , Eritropoetina/efeitos adversos , Hormônio do Crescimento Humano/efeitos adversos , Neoplasias Urológicas/induzido quimicamente , Adolescente , Antagonistas Adrenérgicos beta/administração & dosagem , Antagonistas Adrenérgicos beta/efeitos adversos , Antagonistas Adrenérgicos beta/farmacologia , Anabolizantes/administração & dosagem , Anabolizantes/farmacologia , Animais , Inibidores da Aromatase/administração & dosagem , Inibidores da Aromatase/efeitos adversos , Inibidores da Aromatase/farmacologia , Transformação Celular Neoplásica/efeitos dos fármacos , Estimulantes do Sistema Nervoso Central/administração & dosagem , Estimulantes do Sistema Nervoso Central/efeitos adversos , Estimulantes do Sistema Nervoso Central/farmacologia , Diuréticos/administração & dosagem , Diuréticos/efeitos adversos , Diuréticos/farmacologia , Sinergismo Farmacológico , Eritropoetina/administração & dosagem , Eritropoetina/farmacologia , Feminino , Hormônios/administração & dosagem , Hormônios/efeitos adversos , Hormônio do Crescimento Humano/administração & dosagem , Hormônio do Crescimento Humano/farmacologia , Humanos , Fator de Crescimento Insulin-Like I/fisiologia , Masculino , Neoplasias Experimentais/induzido quimicamente , Risco , Transtornos Relacionados ao Uso de Substâncias/complicações , Adulto Jovem
7.
J Biomater Sci Polym Ed ; 19(9): 1111-23, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18727855

RESUMO

The aim of this study was to design a functional bio-engineered material to be used as scaffold for autologous mesenchymal stem cells in ligament tissue engineering. Polyelectrolyte modified HEMA hydrogel (HEMA-co-METAC), applied as coating on silk fibroin fibres, has been formulated in order to take advantage of the biocompatibility of the polyelectrolyte by increasing its mechanical properties with silk fibres. Human bone marrow mesenchymal stem cells behaviour on such reinforced polyelectrolyte has been studied by evaluating cell morphology, cell number, attachment, spreading and proliferation together with collagen matrix production and its mRNA expression. Silk fibroin fibres matrices with HEMA-co-METAC coating exhibited acceptable mechanical behaviour compared to the natural ligament, good human mesenchymal stem cell adhesion and with mRNA expression studies higher levels of collagen types I and III expression when compared to control cells on polystyrene. These data indicate high expression of mRNA for proteins responsible for the functional characteristics of the ligaments and suggest a potential for use of this biomaterial in ligament tissue-engineering applications.


Assuntos
Eletrólitos/química , Hidrogéis/química , Ligamentos/anatomia & histologia , Células-Tronco Mesenquimais/fisiologia , Metacrilatos/química , Seda/metabolismo , Engenharia Tecidual/métodos , Adulto , Animais , Materiais Biocompatíveis/química , Materiais Biocompatíveis/metabolismo , Forma Celular , Células Cultivadas , Colágeno Tipo I/genética , Colágeno Tipo I/metabolismo , Colágeno Tipo III/genética , Colágeno Tipo III/metabolismo , Humanos , Ligamentos/patologia , Teste de Materiais , Células-Tronco Mesenquimais/citologia , Polímeros/química , Seda/química , Estresse Mecânico , Engenharia Tecidual/instrumentação , Alicerces Teciduais
8.
Urologia ; 74(4): 197-205, 2007.
Artigo em Italiano | MEDLINE | ID: mdl-21086380

RESUMO

PURPOSE. Congenital abnormalities and acquired disorders can lead to organ damage and loss. Nowadays, transplantation represents the only effective treatment option. However, there is a marked decrease in the number of organ donors, which is even yearly worsening due to the population aging. The regenerative medicine represents a realistic option that allows to restore and maintain the normal functions of tissues and organs. This article reviews the principles of regenerative medicine and the recent advances with regard to its application to the genitourinary tract. RECENT FINDINGS. The field of regenerative medicine involves different areas of technology, such as tissue engineering, stem cells and cloning. Tissue engineering involves the field of cell transplantation, materials science and engineering in order to create functional replacement tissues. Stem cells and cloning permit the extraction of pluripotent, embryonic stem cells offering a potentially limitless source of cells for tissue engineering applications. Most current strategies for tissue engineering depend upon a sample of autologous cells from the patient's diseased organ. Biopsies from patients with extensive end-stage organ failure, however, may not yield enough normal cells. In these situations, stem cells are envisaged as being an alternative source. Stem cells can be derived from discarded human embryos (human embryonic stem cells), from fetal tissue or from adult sources (bone marrow, fat, skin). Therapeutic cloning offers a potentially limitless source of cells for tissue engineering applications. Regenerative medicine and tissue engineering scientists have increasingly applied the principles of cell transplantation, materials science and bioengineering to construct biological substitutes that will restore and maintain normal function in urological diseased and injured tissues such as kidney, ureter, bladder, urethra and penis. CONCLUSIONS. Regenerative medicine offers several applications in acquired and congenital genito-urinary diseases. Tissue engineering, stem cells and, mostly, cloning have been applied in experimental studies with excellent results. Few preliminary human applications have been developed with promising results.

10.
Cell Death Differ ; 12(6): 603-13, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15846373

RESUMO

Recent studies suggest a close relationship between cell metabolism and apoptosis. We have evaluated changes in lipid metabolism on permeabilized hepatocytes treated with truncated Bid (tBid) in the presence of caspase inhibitors and exogenous cytochrome c. The measurement of beta-oxidation flux by labeled palmitate demonstrates that tBid inhibits beta-oxidation, thereby resulting in the accumulation of palmitoyl-coenzyme A (CoA) and depletion of acetyl-carnitine and acylcarnitines, which is pathognomonic for inhibition of carnitine palmitoyltransferase-1 (CPT-1). We also show that tBid decreases CPT-1 activity by a mechanism independent of both malonyl-CoA, the key inhibitory molecule of CPT-1, and Bak and/or Bax, but dependent on cardiolipin decrease. Overexpression of Bcl-2, which is able to interact with CPT-1, counteracts the effects exerted by tBid on beta-oxidation. The unexpected role of tBid in the regulation of lipid beta-oxidation suggests a model in which tBid-induced metabolic decline leads to the accumulation of toxic lipid metabolites such as palmitoyl-CoA, which might become participants in the apoptotic pathway.


Assuntos
Carnitina O-Palmitoiltransferase/antagonistas & inibidores , Proteínas de Transporte/farmacologia , Ácidos Graxos/metabolismo , Mitocôndrias Hepáticas/metabolismo , Proteína Agonista de Morte Celular de Domínio Interatuante com BH3 , Cardiolipinas/metabolismo , Carnitina O-Palmitoiltransferase/metabolismo , Proteínas de Transporte/metabolismo , Inibidores de Caspase , Caspases/metabolismo , Permeabilidade da Membrana Celular/efeitos dos fármacos , Células Cultivadas , Citocromos c/metabolismo , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Humanos , Malonil Coenzima A/metabolismo , Potenciais da Membrana/efeitos dos fármacos , Proteínas de Membrana/genética , Mitocôndrias Hepáticas/genética , Oxirredução/efeitos dos fármacos , Ligação Proteica , Proteínas Proto-Oncogênicas c-bcl-2/genética , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Proteína Killer-Antagonista Homóloga a bcl-2
11.
J Endourol ; 13(8): 587-90, 1999 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-10597131

RESUMO

PURPOSE: This study was conducted by nine urology departments in southern Italy to assess the efficacy of and tolerance to treatment of recurrent urethral stricture using a permanent prosthesis. PATIENTS AND METHODS: Since 1992, 99 prostheses have been implanted to treat inflammatory and iatrogenic (seven departments) or all types (two departments) of urethral strictures. The Urolume Wallstent was used in 94 cases. Three centers implanted more than one prosthesis when this was indicated. Local anesthesia was used by six centers, spinal anesthesia by two, and local or general by one. At three centers, urethrotomy was performed immediately prior to implantation; two centers used dilation to 30F, and two centers performed urethrotomy 24 or 36 hours before implantation. The median follow-up is 29.1 months (range 3-53 months). RESULTS: The results were good in 52%, fair in 34%, and poor in 14% of patients. The maximum flow rate increased >75% in 82% of patients. All departments reported complete reepithelialization of the urethra by 6 months. The short-term complications (7-28 days) were perineal discomfort (86%) and dribbling (14%). The long-term complications were painful erection (44%), mucous hyperplasia (44%), recurring stricture (29%), and incontinence (14%). All departments performed resection for hyperplasia in many cases. CONCLUSION: Permanent urethral endoprostheses can produce excellent results in patients with recurrent urethral strictures.


Assuntos
Cistoscopia/métodos , Próteses e Implantes , Implantação de Prótese/instrumentação , Uretra/cirurgia , Estreitamento Uretral/cirurgia , Adulto , Humanos , Itália , Masculino , Estudos Retrospectivos , Prevenção Secundária , Resultado do Tratamento , Unidade Hospitalar de Urologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...